Effect of calcium channel blocker amlodipine on the intimal-medial thickness of carotid arterial wall in type 2 diabetes

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 6, 1999, Pages 894-896

  Koshiyama, Hiroyuki ^a   Tanaka, Satsuki ^b   Minamikawa, Jun ^b  

^a HYOGO PREFECTURAL AMAGASAKI GENERAL MEDICAL CENTER   (Japan)

^b NONE

Author keywords

Amlodipine; Intimal medial thickness; Type 2 diabetes

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ANTIHYPERTENSIVE THERAPY; ARTERY INTIMA; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; DIABETIC ANGIOPATHY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

AGED; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CAROTID ARTERIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; TUNICA INTIMA; ULTRASONOGRAPHY;

EID: 0033054155     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199906000-00009     Document Type: Article

References (14)

1. Lichtlen PR, Hugenholtz, Rafflenbeul W, et al. Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet 1990;335:1109-13.
2. Kjeldsen K, Stender S. Calcium antagonists and experimental atherosclerosis. Proc Soc Exp Biol Med 1989;190:219-28.
3. Pujia A, Gnasso A, Irace C, Colonna A, Mattioli PL. Common carotid arterial wall thickness in NIDDM subjects. Diabetes Care 1994;17:1330-6.
4. Kawamori R, Yamasaki Y, Matsushima H, et al. Prevalence of carotid atherosclerosis in diabetic patients. Diabetes Care 1992; 15:1290-4.
5. Minamikawa J, Yamauchi M, Tanaka S, Koshiyama H. Carotid arterial intimal-medial thickening and plaque formation in NIDDM. Diabetes Care 1998;21:323-4.
6. Fleckenstein A, Markus F, Zorn J, Fleckenstein-Grün. Amlodipine, a new 1, 4-dihydropyridine calcium antagonist with a particularly strong antihypertensive profile. Am J Cardiol 1989;64:211-341.
7. Nayer W. The antiatherogenic effects of amlodipine. J Cardiovasc Pharmacol 1992;20(suppl A):S51-3.
8. McMurray HF, Chahwala SB. Amlodipine exerts a potent antimigrational effect on aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 1992;20(suppl A):S54-6.
9. Jackson CL, Bush RC, Bower DE. Mechanism of antiatherogenic action of calcium antagonists. Atherosclerosis 1989;80:17-26.
10. Munro E, Patel M, Chan P, et al. Effect of calcium channel blockers on the growth of human vascular smooth muscle cells derived from saphenous vein and vascular graft stenoses. J Cardiovasc Pharmacol 1994;23:779-84.
11. Blocke LH, Matthys H, Emmons LR, Perruchoud A, Erne P, Roth M. Ca channel blockers modulate expression of expression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor genes stimulated by platelet-derived growth factor. Proc Natl Acad Sci USA 1991;88:9041-5.
12. Berr NA, Jakubowicz DJ, Beer RM, Nestler JE. The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab 1993;76:1464-9.
13. Minamikawa J, Yamauchi M, Inoue D, Koshiyama H. Another potential use of troglitazone in noninsulin-dependent diabetes mellitus [Letter]. J Clin Endocrinol Metab 1998;83:1041.
14. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998;83: 1818-20.